{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:27:55Z","timestamp":1783024075166,"version":"3.54.6"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    We report an 81-year-old man with metastatic castration-resistant prostate cancer (mCRPC) after multiple prior therapies, including androgen deprivation therapy (ADT), the androgen receptor pathway inhibitor (ARPI) abiraterone, taxane chemotherapy with docetaxel and cabazitaxel, radiopharmaceutical therapy (RPT) with 4 cycles of [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]PSMA-I&amp;T, and the PARP inhibitor olaparib in combination with abiraterone. Due to biochemical and clinical progression, [\n                    <jats:sup>18<\/jats:sup>\n                    F]PSMA-1007 PET\/CT was performed for restaging, revealing diffuse skeletal metastases without significant extraosseous disease. Based on this imaging pattern, treatment with the ARPI enzalutamide combined with\n                    <jats:sup>223<\/jats:sup>\n                    Ra-dichloride was initiated, resulting in an excellent response with a &gt;90% PSA decline and a progression-free survival of 10 months.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006443","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T14:01:49Z","timestamp":1775656909000},"page":"704-705","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Excellent Response to Combined 223Ra-dichloride and Enzalutamide After Failure of 177Lu-PSMA Radioligand Therapy"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3837-7151","authenticated-orcid":false,"given":"Eduardo","family":"Calder\u00f3n","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena Sophie","family":"Sp\u00e4th","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Maas","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Tuebingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"la Foug\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen"},{"name":"DFG Cluster of Excellence 2180 \u2018Image-Guided and Functional Instructed Tumor Therapy\u2019 (iFIT), University of Tuebingen"},{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils F.","family":"Trautwein","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen"},{"name":"DFG Cluster of Excellence 2180 \u2018Image-Guided and Functional Instructed Tumor Therapy\u2019 (iFIT), University of Tuebingen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"111774","DOI":"10.1016\/j.ejrad.2024.111774","article-title":"PSMA PET\/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients","volume":"181","author":"Kleiburg","year":"2024","journal-title":"Eur J Radiol"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2967\/jnumed.118.215715","article-title":"Early experience of rechallenge (177)Lu-PSMA radioligand therapy after an initial good response in patients with advanced prostate cancer","volume":"60","author":"Gafita","year":"2019","journal-title":"J Nucl Med"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00259-025-07438-1","article-title":"Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"53","author":"Belabaci","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20260702","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"key":"R9-20260702","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","volume":"36","author":"Tombal","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:10:31Z","timestamp":1783023031000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006443","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"2026-01-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}